Japan Tissue Engineering Co., Ltd. (7774.T)
JPY 661.0
(5.93%)
JPY 661.0
(5.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.52 Billion JPY | -18.36% |
| 2022 | 1.86 Billion JPY | 6.33% |
| 2021 | 1.75 Billion JPY | 8.0% |
| 2020 | 1.62 Billion JPY | 14.09% |
| 2019 | 1.42 Billion JPY | -12.92% |
| 2018 | 1.63 Billion JPY | 43.13% |
| 2017 | 1.14 Billion JPY | 25.26% |
| 2016 | 911.67 Million JPY | -29.95% |
| 2015 | 1.3 Billion JPY | -9.65% |
| 2014 | 1.44 Billion JPY | -4.01% |
| 2013 | 1.5 Billion JPY | 20.8% |
| 2012 | 1.24 Billion JPY | 27.53% |
| 2011 | 974.19 Million JPY | 6.01% |
| 2010 | 918.94 Million JPY | -0.26% |
| 2009 | 921.36 Million JPY | -1.33% |
| 2008 | 933.79 Million JPY | 5.41% |
| 2007 | 885.86 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 440.34 Million JPY | 71.92% |
| 2024 Q2 | 438.53 Million JPY | -0.41% |
| 2023 Q1 | 446.14 Million JPY | 0.25% |
| 2023 Q2 | 389.31 Million JPY | -12.74% |
| 2023 FY | 1.52 Billion JPY | -18.36% |
| 2023 Q3 | 395.03 Million JPY | 1.47% |
| 2023 Q4 | 256.13 Million JPY | -35.16% |
| 2022 FY | 1.86 Billion JPY | 6.33% |
| 2022 Q1 | 504.38 Million JPY | 17.56% |
| 2022 Q2 | 449.16 Million JPY | -10.95% |
| 2022 Q3 | 466.11 Million JPY | 3.78% |
| 2022 Q4 | 445.04 Million JPY | -4.52% |
| 2021 Q2 | 429.9 Million JPY | -0.89% |
| 2021 FY | 1.75 Billion JPY | 8.0% |
| 2021 Q1 | 433.74 Million JPY | -11.27% |
| 2021 Q3 | 460.97 Million JPY | 7.23% |
| 2021 Q4 | 429.03 Million JPY | -6.93% |
| 2020 Q3 | 379.67 Million JPY | -1.79% |
| 2020 Q2 | 386.58 Million JPY | 4.84% |
| 2020 Q1 | 368.74 Million JPY | 7.21% |
| 2020 FY | 1.62 Billion JPY | 14.09% |
| 2020 Q4 | 488.83 Million JPY | 28.75% |
| 2019 FY | 1.42 Billion JPY | -12.92% |
| 2019 Q3 | 354.63 Million JPY | -1.74% |
| 2019 Q2 | 360.9 Million JPY | -0.81% |
| 2019 Q1 | 363.85 Million JPY | 8.43% |
| 2019 Q4 | 343.93 Million JPY | -3.02% |
| 2018 Q3 | 320.25 Million JPY | -3.57% |
| 2018 FY | 1.63 Billion JPY | 43.13% |
| 2018 Q1 | 646.56 Million JPY | 101.88% |
| 2018 Q2 | 332.1 Million JPY | -48.64% |
| 2018 Q4 | 335.57 Million JPY | 4.78% |
| 2017 Q3 | 274.7 Million JPY | 1.55% |
| 2017 Q2 | 270.51 Million JPY | -2.17% |
| 2017 FY | 1.14 Billion JPY | 25.26% |
| 2017 Q1 | 276.5 Million JPY | 36.7% |
| 2017 Q4 | 320.26 Million JPY | 16.59% |
| 2016 FY | 911.67 Million JPY | -29.95% |
| 2016 Q4 | 202.27 Million JPY | -1.42% |
| 2016 Q3 | 205.19 Million JPY | -7.3% |
| 2016 Q2 | 221.34 Million JPY | -21.75% |
| 2016 Q1 | 282.85 Million JPY | 30.18% |
| 2015 Q2 | 354.08 Million JPY | -1.56% |
| 2015 Q3 | 370.48 Million JPY | 4.63% |
| 2015 Q4 | 217.27 Million JPY | -41.35% |
| 2015 FY | 1.3 Billion JPY | -9.65% |
| 2015 Q1 | 359.7 Million JPY | -12.27% |
| 2014 Q2 | 321.28 Million JPY | -6.68% |
| 2014 Q4 | 410.02 Million JPY | 12.33% |
| 2014 FY | 1.44 Billion JPY | -4.01% |
| 2014 Q1 | 344.28 Million JPY | -25.86% |
| 2014 Q3 | 365.02 Million JPY | 13.62% |
| 2013 Q3 | 374.67 Million JPY | 11.43% |
| 2013 Q1 | 325.54 Million JPY | 6.19% |
| 2013 FY | 1.5 Billion JPY | 20.8% |
| 2013 Q4 | 464.37 Million JPY | 23.94% |
| 2013 Q2 | 336.24 Million JPY | 3.29% |
| 2012 Q1 | 316.18 Million JPY | 242.58% |
| 2012 FY | 1.24 Billion JPY | 27.53% |
| 2012 Q4 | 306.56 Million JPY | -3.76% |
| 2012 Q3 | 318.54 Million JPY | 5.78% |
| 2012 Q2 | 301.13 Million JPY | -4.76% |
| 2011 FY | 974.19 Million JPY | 6.01% |
| 2011 Q1 | 303.06 Million JPY | 292.78% |
| 2011 Q4 | 92.29 Million JPY | -67.1% |
| 2011 Q3 | 280.49 Million JPY | -5.98% |
| 2011 Q2 | 298.34 Million JPY | -1.56% |
| 2010 Q1 | 273.48 Million JPY | 188.7% |
| 2010 Q3 | 295.46 Million JPY | 8.29% |
| 2010 Q4 | 77.15 Million JPY | -73.89% |
| 2010 Q2 | 272.83 Million JPY | -0.24% |
| 2010 FY | 918.94 Million JPY | -0.26% |
| 2009 FY | 921.36 Million JPY | -1.33% |
| 2009 Q3 | 254.24 Million JPY | -8.62% |
| 2009 Q2 | 278.21 Million JPY | -5.43% |
| 2009 Q1 | 294.17 Million JPY | 243.49% |
| 2009 Q4 | 94.73 Million JPY | -62.74% |
| 2008 FY | 933.79 Million JPY | 5.41% |
| 2008 Q3 | 279.65 Million JPY | -0.01% |
| 2008 Q2 | 279.66 Million JPY | -3.17% |
| 2008 Q1 | 288.82 Million JPY | 0.0% |
| 2008 Q4 | 85.64 Million JPY | -69.37% |
| 2007 FY | 885.86 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -18.514% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -163.911% |
| GNI Group Ltd. | 9.32 Billion JPY | 83.671% |
| Linical Co., Ltd. | 2.7 Billion JPY | 43.728% |
| Trans Genic Inc. | 2.15 Billion JPY | 29.519% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -2.087% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 50.432% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 18.024% |
| AnGes, Inc. | 8.9 Billion JPY | 82.9% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -61.415% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 92.067% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -268.599% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -56.072% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 40.711% |
| CanBas Co., Ltd. | 278 Million JPY | -447.582% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -33.354% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 16.264% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 5.081% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 35.879% |
| PeptiDream Inc. | 9.68 Billion JPY | 84.286% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 22.356% |
| Ribomic Inc. | 1.1 Billion JPY | -37.677% |
| SanBio Company Limited | 4.53 Billion JPY | 66.462% |
| Healios K.K. | 3.48 Billion JPY | 56.344% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -31.829% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -14.074% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -8.466% |
| StemRIM | 2.07 Billion JPY | 26.673% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 22.471% |
| FunPep Company Limited | 313.82 Million JPY | -385.078% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -58.9% |
| Stella Pharma Corporation | 963.98 Million JPY | -57.915% |
| TMS Co., Ltd. | 943.25 Million JPY | -61.386% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -39.665% |
| Cuorips Inc. | 598.11 Million JPY | -154.511% |
| K Pharma,Inc. | 543.94 Million JPY | -179.86% |
| Takara Bio Inc. | 23.9 Billion JPY | 93.632% |
| ReproCELL Incorporated | 1.51 Billion JPY | -0.546% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -28.572% |
| StemCell Institute Inc. | 1.16 Billion JPY | -30.991% |
| CellSeed Inc. | 804.93 Million JPY | -89.119% |